Teclistamab

What it is used for

TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma

• in combination with daratumumab and hyaluronidase-fihj in patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
• as monotherapy, in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Side effects, and when to stop

The following adverse reactions are also described elsewhere in the labeling:

• Cytokine Release Syndrome
• Neurologic Toxicity including ICANS
• Hepatotoxicity
• Infections
• Neutropenia
• Hypersensitivity and Other Administration Reactions

Who should not take it

None.

Other medicines and interactions

TECVAYLI causes release of cytokines that may suppress activity of certain cytochrome P450 (CYP) enzymes, resulting in increased exposure of CYP substrates, which may increase the risk of adverse reactions of the CYP substrates. The highest risk of drug-drug interaction is expected to occur after initiation of TECVAYLI step-up dosing schedule up to 7 days after the first treatment dose and during and after CRS.

Monitor for toxicity and/or concentrations of CYP substrates where minimal increases in concentration may lead to serious adverse reactions. Consider decreasing the dosage of the concomitant CYP substrate as needed.

Storing it

Store refrigerated at 2 °C to 8 °C (36 °F to 46 °F) in the original carton to protect from light.

Do not freeze.